Cargando…
Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents
Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of...
Autores principales: | Thomsen, Henrik S., Marckmann, Peter, Logager, Vibeke B. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
e-Med
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072086/ https://www.ncbi.nlm.nih.gov/pubmed/17905680 http://dx.doi.org/10.1102/1470-7330.2007.0019 |
Ejemplares similares
-
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
por: Thomsen, Henrik S.
Publicado: (2006) -
Nephrogenic systemic fibrosis (NSF): the role of tamoxifen
por: Davison, Rachel, et al.
Publicado: (2010) -
An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis
por: Zhang, Bin, et al.
Publicado: (2015) -
Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease
por: Bennett, Charles L., et al.
Publicado: (2012) -
Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure
por: Pieringer, Herwig, et al.
Publicado: (2008)